Jpmorgan Chase & CO Trevena Inc Transaction History

Jpmorgan Chase & CO

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 11, 2022	SELL	$0.2 - $0.5 $15,339 - $38,348	-76,696 Reduced 99.88%	93 $0
Q1 2022 May 11, 2022	BUY	$0.41 - $0.63 $5,088 - $7,818	12,411 Added 19.28%	76,789 $42,000
Q4 2021 Feb 10, 2022	SELL	$0.57 - $1.29 $18,767 - $42,474	-32,926 Reduced 33.84%	64,378 $37,000
Q3 2021 Nov 12, 2021	BUY	$1.11 - $1.7 $108,007 - $165,416	97,304 New	97,304 $119,000

Ticker TRVN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 173,680,992
Market Cap $292M
Description
Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV...

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

Stay updated on Jpmorgan Chase & CO with notifications on news.